Insider trade

Phio Pharmaceuticals (PHIO): Director bought ~$5.7K

David H Deming, Director at Phio Pharmaceuticals, bought ~$5.7K of Phio Pharmaceuticals shares.

~$5.7K
Approx. value · 6,800 sh @ $0.8395
45K
Holds after · shares reported
Traded
Nov 10, 2026
Filed
Nov 12, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Sep 15, 2026Insider · 13 days before an 8-KDirector purchased ~$12K of PHIO shares in the open market
  2. Sep 22, 2026Insider · 6 days before an 8-KCEO purchased ~$2.1K of PHIO shares in the open market
  3. Sep 24, 2026Insider · 4 days before an 8-KDirector purchased ~$6.6K of PHIO shares in the open market
  4. Sep 28, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“Phio Pharmaceuticals Corp. (the “Company”) held its 2026 Annual Meeting of Stockholders via live webcast (the “Annual Meeting”) on September 28, 2026.”
  5. Sep 28, 2026Insider · 3 insiders in a week, 2nd time since 2013Director purchased ~$5.2K of PHIO shares in the open market
  6. Sep 29, 2026InsiderDirector purchased ~$5.2K of PHIO shares in the open market
  7. Nov 5, 2026Company filing · Form 8-K · ResultsReported its results
  8. Nov 9, 2026Insider · 2 peopleInsiders: 2 purchases (~$36K)
  9. Nov 10, 2026 · this disclosureInsider · 3 insiders in a week, 3rd time since 2013Director purchased ~$5.7K of PHIO shares in the open market

What came next

  1. Nov 11, 2026Insider · 3 insiders in a week, 3rd time since 2013Director purchased ~$4.4K of PHIO shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Phio Pharmaceuticals

For Phio Pharmaceuticals, OQRO holds 11 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PHIO page.

Other recent filings by David H Deming, Director

The full history of David H Deming, Director is on the profile page.

How this filing works

Explore the data

Other disclosures at Phio Pharmaceuticals

Everything OQRO holds on this company is on its PHIO page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data